Sanofi unveils fresh insights from its extensive multiple sclerosis (MS) clinical pipeline, investigating various strategies to tackle significant unmet patient requirements.
Sanofi is set to unveil new data during the 9th Joint ECTRIMS-ACTRIMS meeting, presenting evaluations of investigational treatments for multiple sclerosis (MS). These treatments aim to target the underlying biology of MS and address smoldering neuroinflammation, a key driver of disability progression.
The findings will include data on tolebrutinib, an oral investigational Bruton’s tyrosine kinase (BTK) inhibitor with potential as a near-term candidate. This data emphasizes its ability to reach the central nervous system (CNS) and combat smoldering neuroinflammation at its source.
Additionally, data from frexalimab, a novel second-generation investigational anti-CD40L antibody, and SAR443820, the first-in-class oral investigational brain-penetrant receptor-interacting protein kinase 1 (RIPK1) inhibitor, will be presented.
Dr. Erik Wallstroem, Global Head of Neurology Development at Sanofi, commented on the potential of these treatments to address the unmet needs of MS patients by targeting neuroinflammation within the CNS, potentially limiting the debilitating nature of the disease.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
